Attention-Deficit Hyperactivity Disorder (ADHD) Study With Adults

GlaxoSmithKline (GSK)

Status and phase: Completed; Phase 3

Conditions: Attention Deficit Disorder

Treatments: Drug: Extended-release bupropion hydrochloride

Study type: Interventional

Funder types: Industry

Identifiers

NCT00048360

AK130934

Details and patient eligibility

About

This is a placebo controlled study evaluating the efficacy and safety of medication in adults with Attention-Deficit Hyperactivity Disorder (ADHD).

Sex: All

Ages: 18 to 60 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patient must be diagnosed with ADHD.

Exclusion criteria

• Patient has a current or past history of seizure disorder, brain injury, anorexia nervosa or bulimia.
• Patient has a current diagnosis of Major Depressive Disorder (MDD).
• Patient has a current primary diagnosis of, or received treatment for, Panic Disorder, Obsessive Compulsive Disorder (OCD), Posttraumatic Stress Disorder (PTSD) or Acute Stress Disorder within the previous 12 months.
• Patient has a lifetime diagnosis of bipolar disorder, schizophrenia or other psychotic disorders.
• Patient has a positive urine test at screening for presence of illicit drugs or alcohol abuse during the past 12 months.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind